{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007305","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.582741+00:00","generated_at":"2026-06-18T07:27:10.205708+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"TOI Q4 revenue $71M (+36.6% YoY), net loss narrows; beats revised 2022 guidance","bullets":["Q4 2022 revenue $71M (+36.6% YoY); gross profit $16M (+87.6% YoY); net loss $9.5M vs $10.2M prior year.","Adjusted EBITDA loss improved to $(4.6)M from $(5.6)M in Q4 2021.","Ended FY2022 with $132M cash; completed $110M Deerfield investment in Aug 2022.","Surpassed top end of revised 2022 guidance for revenue, gross profit, and adjusted EBITDA.","Market count expanded to 15 from 10; capitated membership added 100k+ lives."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007305","json":"https://secwatch.observer/filing/0001628280-23-007305.json","markdown":"https://secwatch.observer/filing/0001628280-23-007305.md","text":"https://secwatch.observer/filing/0001628280-23-007305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/0001628280-23-007305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/toi-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:27:10.205708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"676c65edd54b9265e1f28f8495da65abdc576e94","claim":"Oncology Institute, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $71 million, net income $9.5 million, EPS $(0.11) and $(0.15).","evidence_excerpt":"• Consolidated revenue of $71 million, an increase of 36.6% from $52 million compared to the prior year quarter • Gross profit of $16 million, an increase of 87.6% compared to the prior year quarter • Net loss of $9.5 million compared to net loss of $10.2 million for the prior year quarter • Basic and diluted earnings per share of $(0.11) and $(0.15), respectively, compared to $(0.13) for the prior year quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/0001628280-23-007305-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$71 million"},{"label":"Net income","value":"$9.5 million"},{"label":"EPS","value":"$(0.11) and $(0.15)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"710b5dbe965414b32037d1cad7dbb53de246025e","claim":"Oncology Institute, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/0001628280-23-007305-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}